RxDoctor Payments Data

Michael Matthews, MD

Family Medicine · Sidney, NENPI 1821177726

Payments from drug & device makers

$992in general payments, 2019–2025

Across 58 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$135
  • Novartis$125
  • Takeda Pharmaceuticals U.S.A., Inc.$103
  • Lilly USA, LLC$97
  • Pfizer$68
  • Boehringer Ingelheim$67
  • plus $397 from 14 others

What the payments were for

  • Food & beverage$95496%
  • Education$384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$992 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$4,122
Medicare patients
23
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban201$133,470
OzempicSemaglutide99$93,324
JardianceEmpagliflozin105$69,857
FarxigaDapagliflozin Propanediol69$46,663
TrulicityDulaglutide40$39,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$34,297
MyrbetriqMirabegron36$18,978
LinzessLinaclotide34$17,295
XareltoRivaroxaban29$17,182
TradjentaLinagliptin23$13,982
Spiriva RespimatTiotropium Bromide18$13,180
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$12,495
JanuviaSitagliptin Phosphate15$12,327
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$10,329
Breo ElliptaFluticasone/Vilanterol25$10,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$68$136,267220 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$67$97,019146 claims
Novo NordiskOzempic$45$93,32499 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$59$68,073114 claims
GSKTrelegy Ellipta, Breo Ellipta$13$44,30877 claims
Lilly USA, LLCTrulicity$97$39,06640 claims
AbbVieLinzess$135$17,29534 claims
Johnson & JohnsonXarelto$50$17,18229 claims
MerckJanuvia$29$12,32715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Sidney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →